1. Home
  2. NIM vs LPTX Comparison

NIM vs LPTX Comparison

Compare NIM & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NIM
  • LPTX
  • Stock Information
  • Founded
  • NIM 1992
  • LPTX 2011
  • Country
  • NIM United States
  • LPTX United States
  • Employees
  • NIM N/A
  • LPTX N/A
  • Industry
  • NIM Trusts Except Educational Religious and Charitable
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NIM Finance
  • LPTX Health Care
  • Exchange
  • NIM Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • NIM 112.0M
  • LPTX 119.6M
  • IPO Year
  • NIM N/A
  • LPTX N/A
  • Fundamental
  • Price
  • NIM $9.04
  • LPTX $0.53
  • Analyst Decision
  • NIM
  • LPTX Buy
  • Analyst Count
  • NIM 0
  • LPTX 3
  • Target Price
  • NIM N/A
  • LPTX $8.50
  • AVG Volume (30 Days)
  • NIM 35.4K
  • LPTX 1.4M
  • Earning Date
  • NIM 01-01-0001
  • LPTX 03-17-2025
  • Dividend Yield
  • NIM 3.46%
  • LPTX N/A
  • EPS Growth
  • NIM N/A
  • LPTX N/A
  • EPS
  • NIM N/A
  • LPTX N/A
  • Revenue
  • NIM N/A
  • LPTX N/A
  • Revenue This Year
  • NIM N/A
  • LPTX N/A
  • Revenue Next Year
  • NIM N/A
  • LPTX N/A
  • P/E Ratio
  • NIM N/A
  • LPTX N/A
  • Revenue Growth
  • NIM N/A
  • LPTX N/A
  • 52 Week Low
  • NIM $8.28
  • LPTX $0.50
  • 52 Week High
  • NIM $9.74
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • NIM 66.26
  • LPTX 17.79
  • Support Level
  • NIM $8.88
  • LPTX $2.03
  • Resistance Level
  • NIM $9.03
  • LPTX $2.39
  • Average True Range (ATR)
  • NIM 0.10
  • LPTX 0.24
  • MACD
  • NIM 0.02
  • LPTX -0.24
  • Stochastic Oscillator
  • NIM 74.29
  • LPTX 0.70

About NIM Nuveen Select Maturities Municipal Fund

Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital by investing in an investment-grade quality portfolio of municipal obligations with intermediate characteristics.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Share on Social Networks: